Novartis' Gilenya: Efficacy, Patient Assistance Lie At Heart Of Marketing Push

As Novartis' multiple sclerosis treatment Gilenya (fingolimod) hits the market, the company is hoping to move beyond the fact that the drug is the first-ever oral drug for general treatment for the disease and highlight its clinical efficacy compared with other MS drugs.